ArticleEuropean heart journal. Case reports2025
Comprehensive treatment strategy in a patient with systemic lupus erythematosus-related pulmonary artery hypertension: a case report.
Article in European heart journal. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Developing a new assessment model for systemic lupus erythematosus disease activity based on a case cohort.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although the prognosis in systemic lupus erythematosus (SLE) has dramatically improved, pulmonary artery hypertension (PAH) is one of the life-threatening comorbidities associated with SLE. The management of the comorbidity is occasionally challenging due to the lack of consensus regarding treatment options including immunosuppressive agents, selective pulmonary vasodilators, and cardiac rehabilitation. Case summary: A 28-year-old female who terminated prednisolone after remission of SLE by her own discretion 3 years ago developed dyspnoea on effort. Transthoracic echocardiography showed dilatation of the right atrium (RA) and ventricle (RV), as well as the RV dysfunction. The findings of right heart catheterization and pulmonary perfusion scintigraphy confirmed PAH associated with connective tissue disease. According to the SLE Disease Activity Index (SLEDAI) and the REVEAL Registry Risk Score, she was at high risk of PAH despite mild SLE activity. Upfront combination therapy including macitentan and tadalafil for PAH and steroid semi-pulse and cyclophosphamide pulse therapy for SLE alongside supervised cardiac rehabilitation were initiated simultaneously. The RA and RV sizes were normalized after the aforementioned therapy. The RV-pulmonary artery (PA) coupling improved from 0.15 to 0.77 mm/mmHg, and the mean PA pressure decreased from 55 to 29 mmHg. Discussion: The case presentation highlighted the potential benefits of comprehensive treatment strategy including immunosuppressive treatment, upfront combination therapy, and supervised exercise training. Notably, the initiation of cardiac rehabilitation at the early phase did not exacerbate her condition and might have contributed to remission of symptoms and improvement in exercise tolerance. This multidisciplinary approach achieved long-term good quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.